Eye­Point and Rally­bio shake hands on col­lab­o­ra­tion; Sh­iono­gi ex­pects bil­lions for Covid an­tivi­ral pill — re­port

Eye­Point Phar­ma­ceu­ti­cals and Rally­bio will be en­ter­ing in­to a part­ner­ship.

The deal will look at the de­liv­ery of Rally­bio’s C5 in­hibitor us­ing Eye­Point’s tech for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA